Stock listing

Lang & Schwarz:A41AKJ NextCure, Inc. Aktie

German listing (Lang & Schwarz) of NextCure, Inc. · home listing NASDAQ:NXTC

Follow NextCure, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:NXTC

$6.45 USD -0.43 (-6.3%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:NXTC

Past year -30.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$6.45 – $6.96 USDNov 20, 2026
Volume
30,624 sharesNov 20, 2026
Market cap
$29.53M USDAt the close on Nov 20, 2026 · price × 4.58M shares outstanding
52-week range
$1.55 – $15.74 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$485,922 USDMedian day 71,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
NextCure, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:NXTC · Home$6.45 USD-0.435 (-6.3%)30,624$6.60$6.96$6.45$6.885Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NXTC · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$6.45-0.435-6.3%$6.60$6.96$6.4530,624
$6.885+0.185+2.8%$6.38$7.005$6.3821,403
$6.70+0.02+0.3%$6.75$7.25$6.3878,011
$6.68+0.28+4.4%$6.085$6.99$5.7537,744
$6.40+0.17+2.7%$6.14$6.57$6.1437,678
$6.23+0.25+4.2%$5.95$6.30$5.3743,034
$5.980.000.0%$5.757$6.30$5.00893,166
$5.98-0.29-4.6%$6.15$6.29$5.6081,524
$6.27+0.94+17.6%$5.46$6.35$5.30558,474
$5.33+0.21+4.1%$5.415$5.71$5.1049,805
$5.12-0.73-12.5%$5.545$5.59$5.1024,057
$5.85-0.06-1.0%$6.01$6.435$5.4138,975
$5.91+0.215+3.8%$5.71$6.04$5.6033,131
$5.695-0.615-9.7%$6.41$6.51$5.3364,063
$6.31-0.215-3.3%$6.32$6.58$6.2419,106
$6.525+0.185+2.9%$6.06$6.66$5.84458,256
$6.34+0.625+10.9%$5.72$6.41$5.62764,391
$5.715+0.49+9.4%$5.305$5.785$4.86142,061
$5.225+0.245+4.9%$4.91$5.48$4.77625,195
$4.98+0.26+5.5%$4.96$5.28$4.52948,500
$4.72-0.695-12.8%$5.28$5.85$4.6171,100
$5.415-0.025-0.5%$5.51$6.042$5.2571,500
$5.44-0.23-4.1%$5.87$6.10$5.32782,100
$5.67-0.57-9.1%$6.16$6.46$5.4567,300
$6.24-0.64-9.3%$6.615$6.66$6.0839,000
$6.88+0.30+4.6%$6.593$7.22$6.59372,400
$6.58+0.30+4.8%$6.16$6.858$6.1151,600
$6.28-0.36-5.4%$6.58$6.80$6.2154,700
$6.64-0.54-7.5%$7.08$7.52$6.03130,400
$7.18+0.40+5.9%$6.675$7.20$6.3085,700
$6.78+0.22+3.4%$6.24$6.94$6.04882,600
$6.56+0.875+15.4%$5.70$6.72$5.42109,500
$5.685+0.635+12.6%$5.01$5.905$5.00122,500
$5.05-0.04-0.8%$5.05$5.19$4.9414,600
$5.09+0.13+2.6%$5.17$5.40$4.8563,300
$4.96-0.05-1.0%$4.99$5.19$4.8546,500
$5.01+0.165+3.4%$5.14$5.165$4.9134,100
$4.845-0.235-4.6%$5.00$5.22$4.7855,400
$5.080.000.0%$5.02$5.305$5.0063,200
$5.08-0.20-3.8%$5.27$5.56$5.02371,800
$5.28+0.46+9.5%$4.80$5.65$4.80226,800
$4.82-0.36-6.9%$5.12$5.19$4.64225,800
$5.18-0.28-5.1%$5.59$5.90$4.87156,100
$5.46-0.66-10.8%$6.09$6.30$5.32125,900
$6.12+0.45+7.9%$5.87$6.27$5.67103,200
$5.67-0.36-6.0%$6.05$6.38$5.54106,800
$6.03-0.34-5.3%$6.55$6.63$5.765106,700
$6.37-0.27-4.1%$6.65$6.735$6.06157,400
$6.64-0.36-5.1%$6.82$7.00$6.2090,600
$7.00-0.31-4.2%$7.33$7.78$6.88115,300
$7.31-0.76-9.4%$7.99$8.17$7.05555,800
$8.07-0.35-4.2%$8.57$8.57$7.6942,900
$8.42+0.60+7.7%$7.47$8.64$7.0595,000
$7.82-0.02-0.3%$7.79$8.23$7.5760,600
$7.84+0.49+6.7%$7.48$8.30$7.106161,400
$7.35+0.55+8.1%$6.70$7.44$6.475112,600
$6.80+0.41+6.4%$6.38$6.86$6.16112,900
$6.39+0.30+4.9%$6.13$6.58$6.07854,700
$6.09+0.055+0.9%$5.98$6.20$5.9360,800
$6.035+0.205+3.5%$5.95$6.34$5.93273,300
$5.83-0.08-1.4%$5.85$6.19$5.6091,100
$5.91+0.02+0.3%$5.93$6.759$5.84160,415
$5.89-0.40-6.4%$6.20$6.629$5.69121,650
$6.29+0.04+0.6%$6.19$6.58$6.1937,000
$6.25-0.53-7.8%$6.55$6.725$6.0086,000

Splits

1 split · NASDAQ:NXTC · every price before a split is adjusted for it

DayRatioWhat
1-for-12Consolidation
Ticker
Lang & Schwarz:A41AKJ
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Latest news

All NextCure, Inc. news

NextCure, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
11 in the last 12 months · 79 in all · newest Nov 10, 2026 · oldest 2019
Decks
15 decks · latest Aug 10, 2026

Where NextCure, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:NXTC · Home listingNASDAQUnited StatesUSD
BOATS:NXTCBOATSUnited StatesUSD
Frankfurt:2US0FrankfurtGermanyEUR
gettex:2US0gettexGermanyEUR
Lang & Schwarz:A41AKJ · This pageLang & SchwarzGermanyEUR
LS Exchange:A41AKJLS ExchangeGermanyEUR
Munich:2US0MunichGermanyEUR

Valuation

Price/book 5.4× against a median of 2.0×: 8th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$20.81M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
5.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.85

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
NextCure, Inc. · NASDAQ:NXTCUS$29.53MUS$20.81Mn/an/an/a5.4×n/a0.0×1.85
Kalaris Therapeutics, Inc. · NASDAQ:KLRSUS$30.47M−US$51.05Mn/an/an/a0.6×n/a0.0×0.47
Pacific Software, Inc. · OTC:PFSFUS$29.86MUS$38.10Mn/an/an/an/an/an/a1.57
NurExone Biologic Inc · TSXV:NRXUS$29.53MUS$28.52Mn/an/an/a23.3×n/a0.0×0.00
BioHarvest Sciences, Inc. · NASDAQ:BHSTUS$29.47MUS$34.54Mn/a1.0×n/a1.8×−34.7%1.0×0.43
Thiogenesis Therapeutics Corp · TSXV:TTIUS$29.28MUS$24.21Mn/an/an/a6.2×n/a0.0×0.37
NanoViricides, Inc. · AMEX:NNVCUS$29.11MUS$26.54Mn/an/an/a4.5×n/a0.0×1.82
Rein Therapeutics, Inc. · NASDAQ:RNTXUS$29.06M−US$6.43Mn/an/an/a0.6×n/a0.0×2.11
Nicox SA · EURONEXT:ALCOXUS$29.05MUS$25.67Mn/a1.4×n/a3.8×−14.4%0.4×n/a
Serina Therapeutics, Inc. · AMEX:SERUS$28.45MUS$12.42Mn/a99.3×n/a2.0×n/a0.2×1.60
ProMIS Neurosciences Inc. · NASDAQ:PMNUS$28.43M−US$15.68Mn/an/an/a0.7×n/a0.0×0.83
Median of the othersUS$29.20MUS$24.94M1.4×2.0×−24.5%0.0×0.83

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
20.00 USD · Analysts' mean
EPS, year to Dec 2026
-6.34 · 1 analyst

Team and board

Officers

OfficerRole
Michael RichmanPresident & CEO
Steven P. CobournCFO
Timothy MayerCOO
Kevin ShawGeneral Counsel
Dallas FliesVice President, Discovery Research
Sebastien MalovesteSenior Vice President, Business Development
Sourav KunduSenior Vice President, Development & Manufacturing

Board

DirectorRole
David KabakoffChairman
Anne BorgmanDirector
Elaine V. JonesDirector
Ellen G. FeigalDirector
John G. HoustonDirector
Michael RichmanPresident & CEO
Stephen WebsterDirector

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · After close0.0%
Q2 2026Aug 6, 2026 · After close+4.5%
Q1 2026May 7, 2026 · After close−4.1%
Q4 2025Mar 6, 2026−2.0%
Q3 2025Nov 5, 2025 · After close+2.0%
Q2 2025Aug 7, 2025 · After close−4.4%
Q1 2025May 1, 2025 · After close−7.7%
Q4 2024Mar 19, 2025 · Before open+0.2%
Q3 2024Nov 7, 2024 · After close−2.3%
Q2 2024Aug 1, 2024 · After close−0.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · After close+2.7%
Q4 2023Mar 21, 2024 · Before open+19.1%
Q3 2023Nov 2, 2023 · After close+0.8%
Q2 2023Aug 3, 2023 · After close−1.2%
Q1 2023May 4, 2023 · After close0.0%
Q4 2022Mar 2, 2023 · After close−4.5%
Q3 2022Nov 3, 2022 · After close−21.1%
Q2 2022Aug 4, 2022 · After close+6.3%
Q1 2022May 5, 2022 · After close−2.1%
Q4 2021Mar 3, 2022 · After close−0.4%

Open Events

Decks

DeckKindSlidesDate
Merger or Acquisition (August 2026)Merger or acquisition21 slidesAug 10, 2026
Merger or Acquisition (August 2026)Merger or acquisition20 slidesAug 4, 2026
Investor Presentation (August 2026)Investor deck16 slidesAugust 2026
Avere Therapeutics — Merger or Acquisition (July 2026)Merger or acquisition20 slidesJuly 2026
Technical Presentation (June 2026)Technical26 slidesJun 2, 2026
Investor Presentation (June 2026)Investor deck31 slidesJun 1, 2026
Investor Presentation (January 2026)Investor deck28 slidesJan 23, 2026
Investor Presentation (June 2025)Investor deck25 slidesJun 16, 2025
Investor Presentation (April 2025)Investor deck16 slidesApr 10, 2025
Investor Presentation (December 2024)Investor deck20 slidesDec 5, 2024
All 15 decks
DeckKindSlidesDate
Investor Presentation (November 2024)Investor deck20 slidesNov 8, 2024
Investor Presentation (March 2024)Investor deck38 slidesMar 21, 2024
Investor Presentation (March 2022)Investor deck27 slidesMar 3, 2022
Corporate Update (November 2021)Corporate update45 slidesNov 15, 2021
Technical PresentationTechnical15 slides

Open Decks

Financings

RaiseDate
Private placement of private placement concurrent with the Merger
Made bigger: about US$820M
Use of proceeds: To advance development of AVR-001 and support future operations of the combined company after the Merger.
Nov 10, 2026
Private placement of shares of common stock and pre-funded warrants
Closed: US$21.5M raised · US$8.52 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Buyers: Ikarian Capital; Squadron Capital Management; Affinity Healthcare Fund, LP.; Exome Asset Management; Affinity Healthcare Fund, LP
Use of proceeds: General working capital, extending cash runway into first half of 2027, beyond first half 2026 proof of concept data readouts of SIM0505 and LNCB74
Nov 17, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$15.00 a share on May 8, 2019.

Price
US$15.00 a share
Shares offered
5,000,000 shares of common stock
Offering size
US$75 million
Underwriters' option
Up to 750,000 more shares
Listing
NXTC on the Nasdaq Global Select Market
Underwriters
MORGAN STANLEY, BofA MERRILL LYNCH, PIPER JAFFRAY · In the order on the cover
Shares delivered
On or about May 13, 2019

Steps

StepWhen
Draft sent to the SEC in confidenceJan 30, 2019
Filed publiclyApr 12, 2019
Amended 3 timesNewest May 8, 2019
Shares registered with an exchangeMay 8, 2019
Declared effective by the SECMay 8, 2019
Final prospectus, with the priceMay 9, 2019

Open IPO · From the cover of the final prospectus (424B4) filed May 9, 2019

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue0000022.4M6.35M00
Cost of revenue2.19M2.87M3.68M4.48M4.30M46.6K34.2M1.68M582.0K
Gross profit-2.19M-2.87M-3.68M-4.48M-4.30M22.4M-27.9M-1.68M-582.0K
Research and development44.9M41.5M47.9M54.2M50.2M46.6M34.2M19.8M13.0M
Selling, general and administrative12.7M15.7M19.7M21.7M20.6M17.0M9.61M3.41M2.60M
Operating income-57.6M-59.7M-67.6M-75.9M-70.8M-41.2M-37.5M-23.2M-15.5M
Depreciation and amortization2.20M2.90M3.70M4.10M4.30M3.40M2.69M1.68M582.0K
EBITDA-55.4M-56.8M-63.9M-71.8M-66.5M-37.8M-34.8M-21.5M-15.0M
Interest expense5.30M77.0K183.0K209.0K25.0K0
Income before tax-55.8M-55.7M-62.7M-74.7M-69.4M-36.6M-33.7M-22.8M-15.5M
Income tax0-5.30M6.96M-3.41M2.52M397.0K0
Net income-55.8M-55.7M-62.7M-74.7M-69.4M-36.6M-33.7M-22.8M-15.5M
Earnings per share, basic-19.65-23.88-2.25-2.69-2.51-1.33-2.15-16.64-8.17
Earnings per share, diluted-19.65-23.88-2.25-2.69-2.51-1.33-2.15-16.64

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents26.0M27.7M13.1M26.6M12.3M32.8M34.1M135.2M8.43M
Short-term investments15.8M40.9M95.2M133.3M207.3M250.7M300.5M00
Receivables100.0K300.0K800.0K700.0K
Inventory-700.0K00
Current assets43.7M71.8M112.7M164.0M227.8M288.0M340.0M135.8M9.42M
Property, plant and equipment3.27M5.46M9.03M11.9M14.0M15.8M12.1M11.4M10.0M
Goodwill00
Total assets50.2M80.9M128.0M184.2M242.4M306.6M356.2M147.6M19.5M
Accounts payable2.01M5.35M2.33M4.27M1.94M3.90M1.86M2.48M1.14M
Current liabilities10.6M9.57M6.88M9.13M6.61M10.3M15.0M10.3M3.12M
Long-term debt1.81M3.33M73.0K460.0K
Total debt5.15M5.95M6.61M003.47M5.00M460.0K964.0K
Total liabilities15.2M15.4M13.6M16.6M9.00M12.9M34.7M32.3M43.9M
Shareholders' equity34.9M65.5M114.4M167.5M233.4M293.7M321.5M-46.9M-24.4M
Shares outstanding3.51M2.33M27.9M27.8M27.7M27.6M27.5M1.37M1.89M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-49.6M-40.8M-53.0M-53.9M-57.3M-45.0M-35.6M7.99M-12.5M
Capital spending0-474.0K-820.0K-2.12M-2.36M-7.13M-3.37M-3.06M-8.65M
Free cash flow-49.6M-41.3M-53.8M-56.0M-59.6M-52.1M-39.0M4.93M-21.2M
Cash from investing25.6M55.3M39.3M68.0M36.6M43.5M-303.9M-3.06M-8.65M
Cash from financing22.3M144.0K154.0K200.0K-3.27M-1.42M243.0M121.4M24.9M
Dividends paid00
Share buybacks200.0K208.0K112.0K238.5M122.2M25.0M
Change in cash-1.75M14.6M-13.5M14.3M-23.9M-2.85M-96.5M126.3M3.69M

Open Financials

Filings

FilingDateTypeFiled with
425Nov 20, 2026Other filingsSEC
8-K · Current reportNov 20, 2026Current reportSEC
425Nov 20, 2026Other filingsSEC
8-K · Current reportNov 20, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
4 · Change in ownershipNov 9, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
EFFECT · Notice that a registration is effectiveNov 9, 2026Other filingsSEC
424B3 · ProspectusNov 6, 2026Offer documentSEC
S-4/A · Registration statement, amendedNov 5, 2026Offer documentSEC
S-4/A · Registration statement, amendedOct 30, 2026Offer documentSEC
8-K · Current reportOct 30, 2026Management or board changeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 20, 2026Big-stake noticeSEC
S-4/A · Registration statement, amendedSep 30, 2026Offer documentSEC
425Sep 25, 2026Other filingsSEC
8-K · Current reportSep 25, 2026Current reportSEC
8-K · Current reportSep 3, 2026Material contractSEC
S-4 · Registration statementAug 18, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 12, 2026Big-stake noticeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
425Aug 10, 2026Other filingsSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
425Aug 4, 2026Other filingsSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 29, 2026Insider tradeSEC
425Jul 16, 2026Other filingsSEC
425Jul 14, 2026Other filingsSEC
8-K · Current reportJul 14, 2026Material contractSEC
8-K · Current reportJun 25, 2026Management or board changeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
8-K · Current reportJun 1, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 5, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 12, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 29, 2026Big-stake noticeSEC
8-K · Current reportJan 23, 2026ResultsSEC
8-K · Current reportDec 19, 2025Current reportSEC
424B5 · ProspectusDec 19, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 12, 2025Other filingsSEC
424B1 · ProspectusDec 11, 2025Offer documentSEC
DDec 9, 2025Other filingsSEC
CORRESP · Letter to the SECDec 9, 2025Other filingsSEC
S-3 · Registration statementNov 26, 2025Offer documentSEC
8-K · Current reportNov 17, 2025Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 24, 2025Big-stake noticeSEC
3/A · Initial statement of ownership, amendedSep 29, 2025Insider tradeSEC
8-K · Current reportAug 25, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeAug 19, 2025Big-stake noticeSEC
3 · Initial statement of ownershipAug 19, 2025Insider tradeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
EFFECT · Notice that a registration is effectiveJul 30, 2025Other filingsSEC
424B2 · ProspectusJul 29, 2025Offer documentSEC
CORRESP · Letter to the SECJul 28, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 24, 2025Other filingsSEC
S-3 · Registration statementJul 18, 2025Offer documentSEC
8-K · Current reportJul 14, 2025Current reportSEC
8-K · Current reportJul 10, 2025Current reportSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
8-K · Current reportJun 23, 2025Meeting outcomeSEC
8-K · Current reportJun 16, 2025Material contractSEC
DEFA14A · Additional proxy materialMay 19, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialMay 19, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 1, 2025Quarterly reportSEC
8-K · Current reportMay 1, 2025ResultsSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 15, 2025Meeting noticeSEC
8-K · Current reportApr 10, 2025Current reportSEC
10-K · Annual reportMar 6, 2025Annual reportSEC
8-K · Current reportMar 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
3 · Initial statement of ownershipFeb 6, 2025Insider tradeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
8-K · Current reportFeb 3, 2025Current reportSEC
8-K · Current reportJan 10, 2025Current reportSEC
8-K · Current reportDec 10, 2024Current reportSEC
8-K · Current reportDec 5, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
8-K · Current reportNov 8, 2024Current reportSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
10-Q · Quarterly reportAug 1, 2024Quarterly reportSEC
8-K · Current reportAug 1, 2024ResultsSEC
SC 13G · Big-stake noticeJun 27, 2024Big-stake noticeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
8-K · Current reportJun 21, 2024Meeting outcomeSEC
8-K · Current reportJun 18, 2024Management or board changeSEC
10-Q · Quarterly reportMay 2, 2024Quarterly reportSEC
8-K · Current reportMay 2, 2024ResultsSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 16, 2024Meeting noticeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
4 · Change in ownershipApr 2, 2024Insider tradeSEC
SC 13G · Big-stake noticeApr 1, 2024Big-stake noticeSEC
10-K · Annual reportMar 21, 2024Annual reportSEC
8-K · Current reportMar 21, 2024ResultsSEC
SC 13D/A · Big-stake notice, amendedMar 8, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 1, 2024Insider tradeSEC
4 · Change in ownershipFeb 1, 2024Insider tradeSEC
4 · Change in ownershipFeb 1, 2024Insider tradeSEC
4 · Change in ownershipFeb 1, 2024Insider tradeSEC
4 · Change in ownershipFeb 1, 2024Insider tradeSEC
4 · Change in ownershipFeb 1, 2024Insider tradeSEC
4 · Change in ownershipFeb 1, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 19, 2024Big-stake noticeSEC
8-K · Current reportDec 14, 2023Current reportSEC
10-Q · Quarterly reportNov 2, 2023Quarterly reportSEC
8-K · Current reportNov 2, 2023ResultsSEC
EFFECT · Notice that a registration is effectiveAug 14, 2023Other filingsSEC
CORRESP · Letter to the SECAug 9, 2023Other filingsSEC
UPLOAD · Letter from the SECAug 8, 2023Other filingsSEC
S-8 · Registration statement for employee plansAug 4, 2023Offer documentSEC
S-3 · Registration statementAug 4, 2023Offer documentSEC
10-Q · Quarterly reportAug 3, 2023Quarterly reportSEC
8-K · Current reportAug 3, 2023ResultsSEC
8-K · Current reportJul 19, 2023Management or board changeSEC
8-K · Current reportJun 26, 2023Meeting outcomeSEC
4 · Change in ownershipJun 23, 2023Insider tradeSEC
4 · Change in ownershipJun 23, 2023Insider tradeSEC
4 · Change in ownershipJun 23, 2023Insider tradeSEC
4 · Change in ownershipJun 23, 2023Insider tradeSEC
4 · Change in ownershipJun 23, 2023Insider tradeSEC
4 · Change in ownershipJun 23, 2023Insider tradeSEC
4 · Change in ownershipJun 23, 2023Insider tradeSEC
4 · Change in ownershipJun 23, 2023Insider tradeSEC
10-Q · Quarterly reportMay 4, 2023Quarterly reportSEC
8-K · Current reportMay 4, 2023ResultsSEC
ARS · Annual report to shareholdersApr 28, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
424B5 · ProspectusApr 3, 2023Offer documentSEC
10-K · Annual reportMar 2, 2023Annual reportSEC
8-K · Current reportMar 2, 2023ResultsSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
4 · Change in ownershipMar 1, 2023Insider tradeSEC
3 · Initial statement of ownershipFeb 28, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2023Big-stake noticeSEC

This page holds 200 of 407 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from NextCure, Inc.’s releases · as of Nov 9, 2026

Common shares
4,579,023
Fully diluted
4,579,023

Fully diluted

LineSharesAs of
Common shares4,579,023Nov 9, 2026

Share count over time

CountShares
Nov 9, 20264,579,023

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
ADAR1 Capital Management, LLC722K15.8%US$3.62MSep 30, 2026
Adage Capital Partners Gp, L.L.C.377K8.2%US$1.89MSep 30, 2026
Affinity Asset Advisors, LLC292K6.4%US$1.46MSep 30, 2026
Blackstone Inc.224K4.9%US$1.12MSep 30, 2026
Sofinnova Investments, Inc.223K4.9%US$1.12MSep 30, 2026
Eversept Partners, LP185K4.1%US$929KSep 30, 2026
Vanguard182K4.0%US$910KSep 30, 2026
Citadel111K2.4%US$554KSep 30, 2026
Verition Fund Management LLC92,9462.0%US$466KSep 30, 2026
Soleus Capital Management, L.P.90,0002.0%US$451KSep 30, 2026
All 32 holders
HolderSharesOf the companyValueAs of
Geode Capital78,1441.7%US$392KSep 30, 2026
Bank of America75,0351.6%US$376KSep 30, 2026
JPMorgan74,4121.6%US$361KSep 30, 2026
Jane Street70,2521.5%US$352KSep 30, 2026
Pfizer Inc44,3570.97%US$225KSep 30, 2026
Renaissance Technologies39,1480.85%US$196KSep 30, 2026
BlackRock36,8200.80%US$184KSep 30, 2026
Millennium26,5260.58%US$133KSep 30, 2026
Morgan Stanley22,9320.50%US$115KSep 30, 2026
Cardiff Park Advisors, LLC21,8330.48%US$109KSep 30, 2026
Prudential Financial Inc17,0910.37%US$85,626Sep 30, 2026
Nomura12,5000.27%US$62,625Sep 30, 2026
Citigroup Inc12,2840.27%US$61,543Sep 30, 2026
Hrt Financial LP12,0200.26%US$60,000Sep 30, 2026
Acadian Asset Management LLC10,6640.23%US$53,000Sep 30, 2026
UBS6,0280.13%US$30,200Sep 30, 2026
Barclays5,6290.12%US$28,201Sep 30, 2026
EverSource Wealth Advisors, LLC1,1140.02%US$5,581Sep 30, 2026
SBI Securities Co., Ltd.1,0000.02%US$5,010Sep 30, 2026
Tower Research Capital LLC (TRC)249<0.01%US$1,247Sep 30, 2026
BNP Paribas32<0.01%US$160Sep 30, 2026
Caitong International Asset Management Co., Ltd18<0.01%US$90Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund123K2.7%US$197KJun 30, 2026
Vanguard Extended Market Index Fund33,5660.73%US$53,706Jun 30, 2026
Fidelity Extended Market Index Fund16,2500.35%US$101KMay 31, 2026
Nomura Healthcare Fund12,5000.27%US$20,000Jun 30, 2026
iShares Micro-Cap ETF9,8510.22%US$15,762Jun 30, 2026
Fidelity Series Total Market Index Fund3,9970.09%US$24,781May 31, 2026
Fidelity Total Market Index Fund3,6340.08%US$22,531May 31, 2026
Ultra-Small Company Market Fund3,0000.07%US$4,800Jun 30, 2026
Fidelity Nasdaq Composite Index Fund2,0470.04%US$12,691May 31, 2026
1290 VT Micro Cap Portfolio7410.02%US$1,186Jun 30, 2026
All 13 holders
HolderSharesOf the companyValueAs of
Diversified Equity Alpha Master Portfolio6890.02%US$1,102Jun 30, 2026
Dimensional U.S. Core Equity 2 ETF59<0.01%US$245Jul 31, 2026
U.S. Micro Cap Portfolio22<0.01%US$91Jul 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
ADAR1 Capital Management, LLC
10% owner
Buy12,333USD 5.10US$62,897Nov 11, 2026
ADAR1 Capital Management, LLC
10% owner
Buy3,662USD 5.10US$18,676Nov 6, 2026
ADAR1 Capital Management, LLC
10% owner
Buy1,024USD 5.10US$5,222Nov 5, 2026
ADAR1 Capital Management, LLC
10% owner
Buy3,553USD 5.10US$18,104Oct 27, 2026
ADAR1 Capital Management, LLC
10% owner
Buy1,672USD 5.03US$8,418Oct 26, 2026
ADAR1 Capital Management, LLC
10% owner
Buy5,626USD 4.83US$27,170Oct 23, 2026
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.
Other: Former 10% Owner
Sale30,000USD 6.16US$185KAug 10, 2026
ADAR1 Capital Management, LLC
10% owner
Buy3,300USD 4.98US$16,434Jul 31, 2026
ADAR1 Capital Management, LLC
10% owner
Buy25,000USD 4.98US$125KJul 31, 2026
ADAR1 Capital Management, LLC
10% owner
Buy8,003USD 4.80US$38,414Jul 31, 2026
All 19 trades
TradeTradeSharesPriceValueDate
ADAR1 Capital Management, LLC
10% owner
Buy50,000USD 4.97US$249KJul 30, 2026
ADAR1 Capital Management, LLC
10% owner
Buy20,000USD 5.00US$100KJul 30, 2026
ADAR1 Capital Management, LLC
10% owner
Buy25,000USD 4.81US$120KJul 30, 2026
ADAR1 Capital Management, LLC
10% owner
Buy100,000USD 4.90US$490KJul 30, 2026
ADAR1 Capital Management, LLC
10% owner
Buy77,850USD 4.96US$386KJul 30, 2026
ADAR1 Capital Management, LLC
10% owner
Buy1,810USD 5.00US$9,050Jul 29, 2026
ADAR1 Capital Management, LLC
10% owner
Buy1,600USD 5.00US$8,000Jul 29, 2026
ADAR1 Capital Management, LLC
10% owner
Buy6,400USD 4.95US$31,680Jul 28, 2026
ADAR1 Capital Management, LLC
10% owner
Buy7,798USD 5.00US$38,990Jul 27, 2026

Big stakes

StakeStakeSharesDateFiling
ADAR1 Capital Management, LLC15.80%722KJul 31, 2026Schedule 13G
Affinity Asset Advisors, LLC9.99%476KSep 30, 2026Schedule 13G
JP Sailing Capital Ltd9.90%455KSep 30, 2026Schedule 13G
Ikarian Capital, LLC9.80%500KSep 30, 2026Schedule 13G
Simcere Zaiming, Inc.9.40%339KDec 31, 2025Schedule 13G
Adage Capital Management, L.P.7.67%277KJun 30, 2026Schedule 13G
Sofinnova Venture Partners IX, L.P. ("SVP IX")7.10%223KDec 19, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Briggs Morrison
Other companies: CRISPR Therapeutics AG (Director · Since at least Jun 5, 2025); Werewolf Therapeutics, Inc. (Director · Since at least Apr 29, 2021); Arvinas, Inc. (Chair of the Arvinas Board of Directors · Since at least Sep 26, 2018); Carisma Therapeutics, Inc. (Director · Mar 7, 2023 – Jun 26, 2024 · Past); Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 17, 2021 · Past); Oncorus Inc (Director · Oct 1, 2020 – Oct 1, 2020 · Past); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 17, 2024 · Past); Syndax Pharmaceuticals, Inc. (Director · Mar 2, 2016 – Feb 7, 2024 · Past)
Director · May 8, 2019 – Jun 11, 2020 · Past
Stephen Webster
Other companies: Cullinan Therapeutics, Inc. (Chair of the Audit Committee · Since at least Jan 7, 2021); Gritstone bio, Inc. (Director · Apr 26, 2024 – Apr 4, 2025 · Past); Tcr2 Therapeutics Inc (Director · Apr 30, 2020 – Jun 1, 2023 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Aug 2, 2022 · Past); Viking Therapeutics, Inc. (Director · Apr 28, 2015 – Jan 2, 2020 · Past); Spark Therapeutics Inc (CHIEF FINANCIAL OFFICER · Jan 29, 2015 – Dec 17, 2019 · Past); Optimer Pharmaceuticals Inc (Chief Financial Officer · Jun 25, 2012 – Oct 24, 2013 · Past); Adolor Corp (SVP, Finance & CFO · Sep 9, 2010 – Dec 12, 2011 · Past)
Director · Since at least May 8, 2019
Timothy M Shannon
Other companies: Rallybio Corporation (Director · Jul 28, 2021 – Jan 3, 2022 · Past); IDEAYA Biosciences, Inc. (Director · May 22, 2019 – Jun 7, 2023 · Past); Arvinas, Inc. (Director · Sep 26, 2018 – Jun 16, 2022 · Past); CytomX Therapeutics, Inc. (Director · Oct 7, 2015 – Nov 29, 2016 · Past); Celldex Therapeutics, Inc. (Director · Oct 1, 2009 – Jun 4, 2014 · Past); Curagen Corp (Former President and CEO, Director · May 25, 2007 – Oct 1, 2009 · Past)
Director · May 8, 2019 – Jun 13, 2019 · Past
Chau Quang Khuong
Other companies: Damora Therapeutics, Inc. (Director · Oct 28, 2020 – Jun 14, 2023 · Past); Fusion Pharmaceuticals Inc (Director · Jun 25, 2020 – Jun 14, 2023 · Past); Whitehawk Therapeutics, Inc. (Director · Jun 18, 2019 – Jun 18, 2019 · Past); Synlogic Inc (Director · Jun 5, 2019 – Apr 20, 2021 · Past); Inspire Medical Systems, Inc. (Director · Apr 10, 2019 – Oct 9, 2020 · Past)
Director · May 8, 2019 – Jun 22, 2023 · Past
Garry A Nicholson
Other companies: TScan Therapeutics, Inc. (Director · Since at least Jun 12, 2024); Day One Biopharmaceuticals Inc (Director · Since at least Sep 12, 2022); G1 Therapeutics Inc (Director · Jun 17, 2021 – Sep 18, 2024 · Past); Turning Point Therapeutics Inc (Director · Jun 2, 2021 – Aug 17, 2022 · Past); Five Prime Therapeutics Inc (Director · Apr 16, 2021 – Apr 16, 2021 · Past)
Director · Jun 24, 2021 – Jun 22, 2023 · Past
Elaine V. Jones
Other companies: CytomX Therapeutics, Inc. (Director · Since at least May 1, 2019); Ibere Pharmaceuticals (Director · Feb 25, 2021 – Feb 25, 2021 · Past); Gritstone bio, Inc. (Director · Sep 12, 2019 – Apr 4, 2025 · Past); Mersana Therapeutics Inc (Director · Jun 27, 2017 – Jun 27, 2017 · Past)
Director · Since at least May 8, 2019
Michael Richman
Other companies: GenVec Inc (Director · Nov 13, 2015 – Jun 16, 2017 · Past); Palvella Therapeutics, Inc. (Director · Jul 15, 2015 – Jun 21, 2023 · Past); Acer Therapeutics Inc (Director · Jun 30, 2015 – Sep 30, 2016 · Past)
President & CEO · Since at least May 8, 2019
Anne Borgman
Other companies: Curis, Inc. (Director · Since at least Oct 12, 2022); Sutro Biopharma, Inc. (CHIEF MEDICAL OFFICER · Feb 28, 2023 – May 1, 2025 · Past)
Director · Since at least Jun 23, 2022
John G. Houston
Other companies: Arvinas, Inc. (Director · Since at least Jul 11, 2019)
Director · Since at least Sep 10, 2020
Dallas FliesVice President, Discovery Research · Since at least Nov 5, 2026
All 20 people
PersonSeat
David KabakoffDirector · Since at least Jun 20, 2024
Ellen G. FeigalDirector · Since at least Nov 5, 2026
Han MyintChief Medical Officer · Jan 11, 2021 – Mar 29, 2024 · Past
Kevin ShawSr VP, General Counsel · Since at least Jan 31, 2024
Sebastien MalovesteSenior Vice President, Business Development · Since at least Nov 5, 2026
Sourav KunduSr VP, Dev. & Mfg. · Since at least Jan 31, 2024
Steven P CobournChief Financial Officer · Since at least Jan 30, 2026
Steven P. CobournCFO · Since at least Nov 4, 2026
Timothy MayerCOO · Since at least Jan 30, 2026
Udayan GuhaChief Medical Officer · Since at least Feb 1, 2025

Open People

Log in to ask 6ix AI your own questions about NextCure, Inc.